This site is intended for healthcare professionals

FDA accepts sNDA for Xywav to treat with idiopathic hypersomnia with PDUFA date on 12 August 2021- Jazz Pharma

Read time: 1 mins
Last updated:13th Apr 2021
Published:13th Apr 2021
Condition: Sleeping Disorders/Idiopathic Hypersomnia
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest